Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (14239)	11/19/2004 7:57:03 PM
From: former_pgs	Read Replies (4) \| Respond to of 52153

>How wonderful to know you're around!..thanks..I knew about the failed naive/chemo combo but not the EGFR status differences..< I'm not trying to be rude or condescending in any way, but I'm really amazed to read this. How could investors be shocked that an EGF-R inhibitor is practically inactive in patients with tumours that do not express EGF-R? How could anyone expect otherwise?

To: zeta1961 who wrote (14239)	11/19/2004 10:11:36 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

Elizabet, more often than not I am wrong than correct. Even when I am correct I am not happy about. I have no opinion on DSCO. Do not follow them. Regards the DNDN, manufacturing problems is in addition to my general concern that they are not up to task that it is in front of them. Maybe, as Rick mentioned, dendrite cells based vaccines have best chances in cancer, but I do not think that DNDN personalized medicine approach is right one. <<Which Iressa data are we waiting for?..>> PIII as br21 trial. Miljenko

To: zeta1961 who wrote (14239)	11/19/2004 11:48:55 PM
From: fred hayes	Read Replies (1) \| Respond to of 52153

Hi Zeta: >I'm not always the humanitarian activist I purport to be<g> < Yes you are. Nothing wrong with taking care of Zeta, too...(:>) fred